Reporting a Population Pharmacokinetic–Pharmacodynamic Study: A Journal’s Perspective

被引:0
|
作者
Kris M. Jamsen
Sarah C. McLeay
Michael A. Barras
Bruce Green
机构
[1] Model Answers Pty Ltd,
[2] Royal Brisbane and Women’s Hospital,undefined
来源
Clinical Pharmacokinetics | 2014年 / 53卷
关键词
Supplementary File; Population Pharmacokinetic Model; Objective Function Value; Visual Predictive Check; Sampling Schedule;
D O I
暂无
中图分类号
学科分类号
摘要
The key purpose of performing pharmacometric research is to aid optimization of drug dosing strategies. The statistical techniques required for this research are advanced, which can make interpretation of results difficult to convey to the target audience if they are unfamiliar with pharmacometric concepts. This article provides a basic guide for authors who wish to publish pharmacometric analyses in peer-reviewed journals. This guide is intended to enhance the readability, reproducibility and understanding of the work for a general readership, which may include clinicians, pharmacists and pharmacometricians. Presentation techniques and examples are offered, as well as a checklist of suggested contents for the manuscript.
引用
收藏
页码:111 / 122
页数:11
相关论文
共 50 条
  • [1] Reporting a Population Pharmacokinetic-Pharmacodynamic Study: A Journal's Perspective
    Jamsen, Kris M.
    McLeay, Sarah C.
    Barras, Michael A.
    Green, Bruce
    CLINICAL PHARMACOKINETICS, 2014, 53 (02) : 111 - 122
  • [2] Guidelines for the Quality Control of Population Pharmacokinetic–Pharmacodynamic Analyses: an Industry Perspective
    P. L. Bonate
    A. Strougo
    A. Desai
    M. Roy
    A. Yassen
    J. S. van der Walt
    A. Kaibara
    S. Tannenbaum
    The AAPS Journal, 2012, 14 : 749 - 758
  • [3] A guide for reporting the results of population pharmacokinetic analyses: A Swedish perspective
    Wade, JR
    Edholm, M
    Salmonson, T
    AAPS JOURNAL, 2005, 7 (02): : E456 - E460
  • [4] A guide for reporting the results of population pharmacokinetic analyses: A Swedish perspective
    Janet R. Wade
    Monica Edholm
    Tomas Salmonson
    The AAPS Journal, 7
  • [5] Population pharmacokinetic and pharmacokinetic/pharmacodynamic modeling of istradefylline
    Rao, Niranjan
    Knebel, William
    Gastonguay, Marc
    Uchimura, Tatsuo
    Bergsma, Tim
    Mori, Akihisa
    NEUROLOGY, 2008, 70 (11) : A60 - A60
  • [6] A regulatory perspective on pharmacokinetic/pharmacodynamic modelling
    Machado, SG
    Miller, R
    Hu, C
    STATISTICAL METHODS IN MEDICAL RESEARCH, 1999, 8 (03) : 217 - 245
  • [7] Guidelines for the Quality Control of Population Pharmacokinetic-Pharmacodynamic Analyses: an Industry Perspective
    Bonate, P. L.
    Strougo, A.
    Desai, A.
    Roy, M.
    Yassen, A.
    van der Walt, J. S.
    Kaibara, A.
    Tannenbaum, S.
    AAPS JOURNAL, 2012, 14 (04): : 749 - 758
  • [8] Deterministic identifiability of population pharmacokinetic and pharmacokinetic–pharmacodynamic models
    Vijay K. Siripuram
    Daniel F. B. Wright
    Murray L. Barclay
    Stephen B. Duffull
    Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44 : 415 - 423
  • [9] Mibefradil pharmacokinetic and pharmacodynamic population analysis
    Welker, HA
    Banken, L
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 1998, 18 (02) : 63 - 71
  • [10] Population pharmacokinetic and pharmacodynamic modeling of norvancomycin
    J. Zhang
    Y. Zhang
    Y. Shi
    J. Rui
    J. Yu
    G. Cao
    J. Wu
    European Journal of Clinical Microbiology & Infectious Diseases, 2008, 27 : 275 - 284